Concert Pharmaceuticals Inc is a leading biopharmaceutical company committed to developing innovative therapies for various diseases. The company's core values revolve around scientific excellence, perseverance, and dedication to patient well-being. With a mission to address unmet medical needs, Concert focuses on discovering and developing small molecule drugs through its proprietary deuterium chemistry platform. By leveraging its expertise, Concert Pharmaceuticals strives to create value for patients, healthcare providers, and shareholders alike. The company's corporate philosophy emphasizes integrity, collaboration, and a patient-centric approach, which are the driving forces behind its continuous pursuit of groundbreaking therapeutic solutions.

Concert Pharmaceuticals Inc is primarily present in the United States.

Concert Pharmaceuticals Inc has achieved several significant milestones. The company successfully advanced its pipeline product, CTP-543, into late-stage development for alopecia areata. Moreover, Concert Pharmaceuticals Inc received FDA Fast Track designation for CTP-543, reinforcing its potential as a promising treatment option. The company also entered into a licensing agreement with Vertex Pharmaceuticals for CTP-656, a next-generation treatment for cystic fibrosis. Furthermore, Concert Pharmaceuticals Inc successfully completed a Phase 1 trial for CTP-692, a potential treatment for schizophrenia. These accomplishments highlight the company's dedication to developing innovative therapies and solidify its position in the pharmaceutical industry.

Concert Pharmaceuticals Inc is a renowned pharmaceutical company with an impressive history and background. Founded in 2006, the company focuses on developing innovative therapies for various medical conditions. Concert Pharmaceuticals Inc has been dedicated to utilizing deuterium chemistry to create novel drugs with improved pharmacokinetic properties. Through strategic collaborations and research, it has successfully advanced its pipeline, including potential treatments for inflammation and central nervous system disorders. With a strong commitment to scientific excellence and a talented team, Concert Pharmaceuticals Inc continues to make significant contributions to the healthcare industry by addressing unmet medical needs and improving patients' lives.

The main competitors of Concert Pharmaceuticals Inc in the market include Biocryst Pharmaceuticals, Kadmon Holdings, Inc., and Ironwood Pharmaceuticals.

Concert Pharmaceuticals Inc is primarily active in the biopharmaceutical industry.

The business model of Concert Pharmaceuticals Inc is focused on the discovery and development of novel small molecule drugs. The company leverages its DCE Platform® (deuterated chemical entity) to create potential new medicines with improved therapeutic properties. With a strong emphasis on targeted therapies, Concert Pharmaceuticals aims to address unmet medical needs across various therapeutic areas. By utilizing its proprietary technology and partnering with pharmaceutical companies, Concert Pharmaceuticals strives to deliver innovative and differentiated treatments to patients.

Concert Pharmaceuticals KGV ir -2,84.

Concert Pharmaceuticals KUV ir 8,89.

AlleAktien kvalitātes vērtējums Concert Pharmaceuticals ir 5/10.

gaidāmā Concert Pharmaceuticals apgrozījums ir 32,38 milj. USD.

gaidāmā Concert Pharmaceuticals peļņa ir -101,39 milj. USD.

Concert Pharmaceuticals Inc is a biopharmaceutical company focused on developing novel drugs for serious diseases. The company's business model is based on the discovery and development of small molecules that modulate the activity of enzymes or receptors to treat underlying pathologies. The company operates in various areas, including oncology, CNS disorders, and inflammatory diseases. In oncology, Concert Pharmaceuticals Inc is developing an innovative antibody-drug conjugate that targets a specific cancer target structure. The goal is to design a targeted cancer therapy that is less toxic to normal cells and has fewer side effects. In the CNS area, the company is working on a drug to treat depressive disorders that increases the activity levels of neurotransmitters such as serotonin and norepinephrine. The company is also developing a drug for schizophrenia, which works by increasing the activity of the glutamate receptor to reduce the symptoms of the disease. Lastly, Concert Pharmaceuticals Inc is developing new therapies for inflammatory diseases by focusing on a specific group of enzymes responsible for the inflammatory process. The company is currently researching a class of drugs that target these enzymes and provide effective anti-inflammatory effects. Additionally, the company also has a portfolio of products already on the market. These include CTP-656, a drug for cystic fibrosis, and CTP-543, a drug for alopecia areata. Both drugs are in Phase 3 of clinical development. Concert Pharmaceuticals Inc's business model relies on collaboration with other companies in the industry. Partners include global pharmaceutical companies that integrate the company's products into their own commercial infrastructures. In addition to partnerships, the company also builds strategic alliances with leading academic research institutions and biotechnology companies to expand its discovery and development activities. The company is funded through public funding and private investors. A significant source of revenue is also the licensing income from the commercialization of developed drugs. After the products are launched in the market, the company generates additional revenue through their sales. Overall, Concert Pharmaceuticals Inc's business model offers significant advantages due to its innovative research and partnerships. By developing products in various areas, the company has numerous opportunities to increase its revenues and continually advance the industry with new innovative therapies.

Concert Pharmaceuticals izmaksā dividendes 0 USD, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Concert Pharmaceuticals vai uzņēmums nedod dividendes.

Concert Pharmaceuticals ISIN ir US2060221056.

Concert Pharmaceuticals WKN ir A1XEAC.

Concert Pharmaceuticals simbols ir CNCE.

Pēdējo 12 mēnešu laikā Concert Pharmaceuticals maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos Concert Pharmaceuticals plāno maksāt dividendes 0 USD apmērā.

Concert Pharmaceuticals pašreizējā dividendu rentabilitāte ir .

Concert Pharmaceuticals maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

Concert Pharmaceuticals pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 USD. Tas atbilst dividendes ražībai 0 %.

Concert Pharmaceuticals tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Concert Pharmaceuticals apmērā 0 USD, kas tika izmaksāta 20.09.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 20.09.2024..

Pēdējās dividendes izmaksa notika 20.09.2024..

Gadā 2023, Concert Pharmaceuticals izmaksāja 0 USD dividendes.

Concert Pharmaceuticals dividendes tiek izmaksātas USD.